MedTrace Logo

Real-world CANadian CUvitru Non-Interventional Study in Subjects Transitioning From Subcutaneous Immunoglobulin (CANCUN)

NCT03716700 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 126

Last updated 2021-03-05

No results posted yet for this study

Summary

This study will provide insights on the infusion parameters, dosing, and experience of participants transitioning to CUVITRU in a real-world setting.

Conditions

  • Primary Immunodeficiency Diseases (PID)

Interventions

BIOLOGICAL

CUVITRU

CUVITRU

Sponsors & Collaborators

  • Baxalta Innovations GmbH, now part of Shire

    collaborator INDUSTRY

  • Baxalta now part of Shire

    lead INDUSTRY

Principal Investigators

  • Study Director · Shire

Eligibility

Min Age
3 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-09-24
Primary Completion
2020-07-23
Completion
2020-07-23

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03716700 on ClinicalTrials.gov